All Stories

  1. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA

    Article • Clinical and Vaccine Immunology, September 2017, ASM Journals

    Dr Nicole Frahm

  2. Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection

    Article • Journal of Virology, July 2015, ASM Journals

    Dr Nicole Frahm

  3. Identification of Effective Subdominant Anti-HIV-1 CD8+ T Cells Within Entire Post-infection and Post-vaccination Immune Responses

    Article • PLoS Pathogens, February 2015, PLOS

    Dr Nicole Frahm

  4. Use of placebos in Phase 1 preventive HIV vaccine clinical trials

    Article • Vaccine, February 2015, Elsevier

    Dr Nicole Frahm

  5. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study

    Article • PLoS ONE, November 2014, PLOS

    Dr Nicole Frahm

  6. Sex Differences in Immune Variables in the RV144 Trial

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  7. HIV-Specific CD8+ T-cell Expansion Potential, but Not Cytotoxic Capacity, Is Associated with Reduced Set Point Viral Loads in Ad5/HIV Vaccinees

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  8. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial

    Article • Journal of Clinical Investigation, October 2014, American Society for Clinical Investigation

    Dr Nicole Frahm

  9. No Increase in Activated T Cells and Limited Increase in Adenovirus-specific T Cells in Colon and Rectal Mucosa Following HIV-1 DNA/rAd5 Immunization

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  10. CD8 + T-cell Mediated HIV Inhibition after Vaccination with a DNA/Recombinant Ad5 (rAd5) HIV Vaccine Is Similar to that Seen in Treated HIV Infection

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  11. An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  12. HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  13. Integrated Systems Biology Analysis Reveals Contrasting Role for Innate Immune Response Genes in Conferring Risk of Infection in RV144 Trial

    Article • AIDS Research and Human Retroviruses, October 2014, Mary Ann Liebert Inc

    Dr Nicole Frahm

  14. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial

    Article • Journal of Clinical Investigation, August 2014, American Society for Clinical Investigation

    Dr Nicole Frahm

  15. The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay

    Article • Journal of Immunological Methods, July 2014, Elsevier

    Dr Nicole Frahm

  16. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials

    Article • Journal of Immunological Methods, July 2014, Elsevier

    Dr Nicole Frahm

  17. Nonlinear Calibration Model Choice between the Four and Five-Parameter Logistic Models

    Article • Journal of Biopharmaceutical Statistics, June 2014, Taylor & Francis

    Dr Nicole Frahm

  18. Measuring inhibition of HIV replication by ex vivo CD8+ T cells

    Article • Journal of Immunological Methods, February 2014, Elsevier

    Dr Nicole Frahm

  19. Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1

    Article • February 2014, Elsevier

    Dr Nicole Frahm

  20. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Article • New England Journal of Medicine, November 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Nicole Frahm

  21. Increased Sequence Coverage through Combined Targeting of Variant and Conserved Epitopes Correlates with Control of HIV Replication

    Article • Journal of Virology, November 2013, ASM Journals

    Dr Nicole Frahm

  22. Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials

    Article • Journal of Immunological Methods, August 2013, Elsevier

    Dr Nicole Frahm

  23. HIV-1 Vaccine-Induced T-Cell Reponses Cluster in Epitope Hotspots that Differ from Those Induced in Natural Infection with HIV-1

    Article • PLoS Pathogens, June 2013, PLOS

    Dr Nicole Frahm

  24. MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load

    Article • PLoS ONE, August 2012, PLOS

    Dr Nicole Frahm

  25. Optimization and qualification of a multiplex bead array to assess cytokine and chemokine production by vaccine-specific cells

    Article • Journal of Immunological Methods, August 2012, Elsevier

    Dr Nicole Frahm

  26. Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

    Article • New England Journal of Medicine, April 2012, New England Journal of Medicine (NEJM/MMS)

    Dr Nicole Frahm

  27. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

    Article • Journal of Clinical Investigation, January 2012, American Society for Clinical Investigation

    Dr Nicole Frahm

  28. Increased Breadth and Depth of Cytotoxic T Lymphocytes Responses against HIV-1-B Nef by Inclusion of Epitope Variant Sequences

    Article • PLoS ONE, March 2011, PLOS

    Dr Nicole Frahm

  29. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

    Article • Nature Medicine, February 2011, Springer Science + Business Media

    Dr Nicole Frahm

  30. Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles

    Article • PLoS Pathogens, February 2011, PLOS

    Dr Nicole Frahm

  31. Young and Early Career Investigators: Report from a Global HIV Vaccine Enterprise Working Group

    Article • Nature Precedings, September 2010, Springer Science + Business Media

    Dr Nicole Frahm

  32. Young and Early Career Investigators: Report from a Global HIV Vaccine Enterprise Working Group

    Article • Nature Precedings, September 2010, Springer Science + Business Media

    Dr Nicole Frahm

  33. Young and Early Career Investigators: Report from a Global HIV Vaccine Enterprise Working Group

    Article • Nature Precedings, September 2010, Springer Science + Business Media

    Dr Nicole Frahm

  34. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies

    Article • AIDS, March 2010, Wolters Kluwer Health

    Dr Nicole Frahm

  35. P08-06 LB. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial

    Article • Retrovirology, October 2009, Springer Science + Business Media

    Dr Nicole Frahm

  36. Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIV‐1 Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa

    Article • Clinical Infectious Diseases, September 2009, Oxford University Press (OUP)

    Dr Nicole Frahm

  37. HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins

    Article • PLoS ONE, August 2009, PLOS

    Dr Mark A Brockman, Dr Nicole Frahm

  38. The role of IFN-γ Elispot assay in HIV vaccine research

    Article • Nature Protocols, March 2009, Springer Science + Business Media

    Dr Nicole Frahm

  39. Contribution of Immunological and Virological Factors to Extremely Severe Primary HIV Type 1 Infection

    Article • Clinical Infectious Diseases, January 2009, Oxford University Press (OUP)

    Dr Nicole Frahm

  40. OA06-06 LB. Evidence of vaccine-induced changes in breakthrough HIV-1 strains from the Step trial

    Article • Retrovirology, January 2009, Springer Science + Business Media

    Dr Nicole Frahm

  41. Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection

    Article • AIDS, July 2008, Wolters Kluwer Health

    Dr Nicole Frahm

  42. Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity

    Article • AIDS, February 2008, Wolters Kluwer Health

    Dr Nicole Frahm

  43. HLA class I supertypes: a revised and updated classification

    Article • BMC Immunology, January 2008, Springer Science + Business Media

    Dr Nicole Frahm

  44. Recognition of HIV-1 Peptides by Host CTL Is Related to HIV-1 Similarity to Human Proteins

    Article • PLoS ONE, September 2007, PLOS

    Dr Nicole Frahm

  45. Extensive HLA class I allele promiscuity among viral CTL epitopes

    Article • European Journal of Immunology, September 2007, Wiley

    Dr Nicole Frahm

  46. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution

    Article • Hepatology, August 2007, Wiley

    Dr Nicole Frahm

  47. HIV viral diversity and escape from cellular immunity

    Article • Current Infectious Disease Reports, March 2007, Springer Science + Business Media

    Dr Nicole Frahm

  48. A Statistical Framework for Modeling HLA-Dependent T Cell Response Data

    Article • PLoS Computational Biology, January 2007, PLOS

    Dr Nicole Frahm

  49. Correction: Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

    Article • PLoS Pathogens, January 2007, PLOS

    Dr Nicole Frahm

  50. Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1

    Article • PLoS Pathogens, January 2007, PLOS

    Dr Nicole Frahm

  51. The challenges of host and viral diversity in HIV vaccine design

    Article • Current Opinion in Immunology, August 2006, Elsevier

    Dr Nicole Frahm

  52. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes

    Article • Nature Immunology, December 2005, Springer Science + Business Media

    Dr Nicole Frahm

  53. Differential Targeting and Shifts in the Immunodominance of Epstein‐Barr Virus–Specific CD8 and CD4 T Cell Responses during Acute and Persistent Infection

    Article • The Journal of Infectious Diseases, November 2005, Oxford University Press (OUP)

    Dr Nicole Frahm

  54. Extensive HLA class I binding promiscuity among EBV- and HIV- derived cytotoxic T lymphocyte epitopes

    Article • Human Immunology, September 2004, Elsevier

    Dr Nicole Frahm

  55. Differences in the Expressed HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses in Infected Chinese and Caucasians

    Article • AIDS Research and Human Retroviruses, May 2004, Mary Ann Liebert Inc

    Dr Nicole Frahm

  56. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection

    Article • Journal of Clinical Investigation, March 2002, American Society for Clinical Investigation

    Dr Nicole Frahm

  57. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection

    Article • Journal of Clinical Investigation, March 2002, American Society for Clinical Investigation

    Dr Nicole Frahm

  58. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection

    Article • Journal of Clinical Investigation, March 2002, American Society for Clinical Investigation

    Dr Nicole Frahm

  59. Listeriolysin O: cholesterol inhibits cytolysis but not binding to cellular membranes

    Article • Molecular Microbiology, June 1998, Wiley

    Dr Nicole Frahm

  60. The defined attenuatedListeria monocytogenes Δmpl2 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma

    Article • European Journal of Immunology, June 1997, Wiley

    Dr Nicole Frahm